The ‘golden rule’ when investing healthcare, is to buy ‘best in class’ technology targeted at large addressable markets. Here Sara Barrington CEO of Verici DX explains why this pioneering immunodiagnostics firm - developing a full suite of next generation pre/post kidney transplant tests - ticks the box.
Key benefits of the Tuteva test Start
Size of the addressable market 06:12
Superior clinical performance of Tuteva vs existing diagnostics 07:11
Positive response from last week's America Transplant Congress 13:01
Update on Clarava & Protega 16:46
Clinical importance of #VRCI's suite of tests 20:35
Commercialisation strategy 22:56
Future newsflow 27:13
Verici DX - Interview with CEO Sara Barrington
Jun 15, 2022Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.